FDA Approves Third of New Migraine Drugs
Sept. 28, 2018 — The FDA has approved the third of a new type of drug to prevent migraine headaches in adults. Galcanezumab-gnlm (Emgality) targets calcitonin gene-related peptide (CGRP), a molecule that’s produced in nerve cells of the brain and spinal cord. The FDA approved two other CGRP drugs for migraine — erenumab (Aimovig) and fremanezumab-vfrm… Read More »